Encision Inc. Reports $6.6 Million Total Revenue and Improved Net Loss for FY25

Encision Inc., a medical device company based in Boulder, Colorado, reported a net product revenue of $6.2 million for the fiscal year ending March 31, 2025, a decrease of 3% from $6.4 million in the previous fiscal year. The company's net service revenue, however, saw a significant increase, rising to $337,628 from $153,913 in the prior year, primarily due to engineering services provided under a Master Services Agreement with Vicarious Surgical Inc. Overall, Encision's total revenue for FY25 was $6.6 million, down slightly from $6.6 million in FY24. The company recorded a net loss of $220,198, an improvement from a loss of $691,783 in FY24, attributed to higher service revenue and reduced operating expenses.

Encision's gross profit increased by 12% to $3.5 million, with a gross profit margin of 54% compared to 48% in the previous year. This improvement was largely due to a reduction in material costs for high-volume products. Sales and marketing expenses rose by 3% to $1.7 million, while general and administrative expenses decreased by 8% to $1.4 million. Research and development expenses also saw a slight decline, totaling $593,152, down from $621,894 in FY24.

The company has made strategic advancements, including the introduction of its AEM EndoShield® 2 Burn Protection System, which enhances patient safety in minimally invasive surgeries. Encision has also signed a Proof-of-Concept Services Agreement with Vicarious Surgical Inc. to integrate AEM technology into robotic surgical systems. The company is focused on expanding its distribution network and increasing market penetration, particularly in the U.S. and international markets, including Australia and New Zealand.

As of March 31, 2025, Encision employed 22 full-time and 2 part-time individuals, a slight increase from the previous year. The company reported that it generated sales from over 400 hospitals that have adopted AEM products. Encision's accumulated deficit stood at $22.8 million, and it had cash and equivalents of $257,433 at the end of the fiscal year. The company is exploring options for additional financing to support its operations and growth initiatives.

Looking ahead, Encision aims to increase sales through a focused marketing campaign highlighting the clinical and economic benefits of AEM technology. The company anticipates that improvements in its sales network and product offerings will contribute to revenue growth in FY26. However, it acknowledges the ongoing need for capital and the potential for operating losses if sales do not meet expectations. Encision's management remains optimistic about the future, citing the unique performance of AEM technology and its growing recognition in the medical community.